文献速递流行病学与生物统计临床试验与 GCP

针对两个二分类共同主要终点的III期随机对照试验中采用人群富集的自适应群序贯设计

Adaptive group-sequential design with population enrichment in phase 3 randomized controlled trials with two binary co-primary endpoints.
PubMed 文献 · Stat Med · 2019-06-11

本文提出一种在III期随机对照试验中针对两个二分类共同主要终点、于中期分析时剔除无响应亚组以实现人群富集的自适应群序贯设计的理论基础与开发方法,给出无效性与有效性的阶段边界值,并讨论不同疗效配置、亚组患病率和分析时间下的把握度。使用每个终点0.025显著性水平,得到I阶段无效性与有效性阈值边界值分别为-0.1040和2.2761,II阶段无效性与有效性边界值为2.2419。

要点

  • 提出针对两个二分类共同主要终点的自适应人群富集设计,中期分析时剔除无响应亚组。
  • 每个终点显著性水平0.025时,I阶段无效性与有效性边界值为-0.1040和2.2761。
  • II阶段无效性与有效性边界值为2.2419。

核心结论

  • 在存在显著治疗效应异质性时,该设计在获益更大的亚组中获得更高把握度观察效应。
  • 通过在早期阶段剔除无响应亚组,该设计降低因纳入两个亚组的异质性治疗效应稀释响应亚组结果而获得假阴性结果的可能性。

研究设计与样本

  • 两组、两阶段、平行组设计,在中期分析时通过剔除任何无响应亚组实现人群富集。
  • 仅在富集人群中开展有效性检验,两个二分类终点作为共同主要终点。
  • 试验目标为确定实验性干预是否优于对照干预,且要求两个终点均显示优效性。
  • 使用alpha消耗函数定义停止边界。

主要发现

  • 使用每个终点0.025显著性水平,I阶段无效性与有效性阈值边界值分别为-0.1040和2.2761。
  • II阶段无效性与有效性边界值为2.2419。
  • 在存在显著治疗效应异质性时,在获益更大的亚组中获得更高把握度观察效应。
  • 通过早期剔除无响应亚组,降低因纳入两个亚组的异质性治疗效应稀释响应亚组结果而获得假阴性结果的可能性。

关键数值与推荐

  • 每个终点显著性水平为0.025。
  • I阶段无效性边界值为-0.1040,有效性边界值为2.2761。
  • II阶段无效性与有效性边界值为2.2419。
  • 两个二分类终点作为共同主要终点,要求两个终点均显示优效性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The use of co-primary endpoints in drug development allows investigators to capture an experimental intervention's multidimensional effect more comprehensively than a single primary endpoint. We propose the theoretical basis and development of an adaptive population enrichment design with co-primary endpoints, provide stage-wise boundary values for futility and efficacy, and discuss power under different efficacy configurations, subgroup prevalence, and analysis times using a pre-specified decision criterion. We considered a two-arm, two-stage, parallel group design where population enrichment occurs at the interim analysis by dropping any non-responsive subgroups. A test for efficacy is conducted only in the enriched population. Two binary endpoints are evaluated as co-primary endpoints. Our trial objective is to determine whether the experimental intervention is superior to the control intervention, with superiority required in both endpoints. We define the stopping boundary using alpha spending functions. Using a 0.025 significance level for each endpoint, we obtain the stage I threshold boundary values for futility and efficacy as -0.1040 and 2.2761, respectively, and the stage II boundary value for futility and efficacy is 2.2419. We show that in the presence of substantial heterogeneity of treatment effect, we gain more power to observe an effect in the subgroup where the benefits are greater. By allowing the dropping of non-responsive subgroups at an early stage, our design reduces the likelihood of obtaining false-negative results due to inclusion of the heterogeneous treatment effects of both subgroups, which would dilute the responsive subgroup's results.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Sinha AK, Moye L, Piller LB, et al. Adaptive group-sequential design with population enrichment in phase 3 randomized controlled trials with two binary co-primary endpoints. Stat Med. 2019. PMID: 31184783. doi:10.1002/sim.8216

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。